2 results
Approved WMOCompleted
Primary aim of the study is to compare the efficacy and safety of two flowrates of ITB while maintaining a constant daily dose.
Approved WMORecruiting
To determine if the addition of midostaurin to daunorubicin/ cytarabine induction, high dose cytarabine consolidation, and continuation therapy improves overall survival (OS) in both the mutant FLT3-ITD and FLT-3 TKD AML patients.